Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
| Revenue (TTM) | $12.59B |
| Gross Profit (TTM) | $6.92B |
| EBITDA | $5.10B |
| Operating Margin | 38.10% |
| Return on Equity | 23.50% |
| Return on Assets | 11.90% |
| Revenue/Share (TTM) | $49.51 |
| Book Value | $79.92 |
| Price-to-Book | 6.46 |
| Price-to-Sales (TTM) | 10.06 |
| EV/Revenue | 9.93 |
| EV/EBITDA | 24.51 |
| Quarterly Earnings Growth (YoY) | 8.00% |
| Quarterly Revenue Growth (YoY) | 12.50% |
| Shares Outstanding | $253.46M |
| Float | $252.68M |
| % Insiders | 0.21% |
| % Institutions | 98.22% |
Volatility is currently expanding
Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Vertex Pharmaceuticals (VRTX) reached $508.75 at the closing of the latest trading day, reflecting a +2.06% change compared to its last close.
Thanks to its most recent acquisition, Vertex now has some promising products in the field of hormone disorders. These could eventually become meaningful growth drivers for the company.
Biotechnology stocks are showing signs of a renewed recovery, supported by a pickup in pharmaceutical mergers and acquisitions and investor interest in drug development pipelines. Key Takeaways: Big pharma acquisitions are hitting record highs to combat impending patent cliffs.
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced new interim data from the ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor) 2 to 5 years old open-label extension study, highlighting recovery of exocrine pancreatic function in some children in that age group, allowing those children to discontinue pancreatic enzyme replacement therapy (PERT). Pancreatic exocrine insufficiency in children with cystic fibrosis (CF) was previously believed to be irreversib.
Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $506.74, marking a -3.07% move from the previous day.
Strong performance across the healthtech sector over the past two quarters has sparked renewed market interest in medical innovation. Given the volume of inquiries landing on our desks, we compiled this guide to answer a mix of the most frequent and most interesting questions we have received regarding our Healthcare Technology and Innovation Index (HTEC).
VRTX is expanding beyond its CF stronghold with a promising kidney disease pipeline led by povetacicept and inaxaplin.
VRTX announces positive AMPLIFIED data for inaxaplin, while completing AMPLITUDE enrollment and targeting interim results in early 2027.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on VRTX and any ticker you trade — then tracks every position and per-strategy win rate.
